BioClin Therapeutic, Inc. , a privately-held clinical drug development company developing a first-in-class anti-FGFR3 (fibroblast growth factor receptor 3) monoclonal antibody in areas of high medical need, today announced the closing of the $30 million Series B funding The financing was led by new investors Sofinnova Ventures and Ysios Capital, including existing investors HealthCap, Life Sciences Partners (LSP) and Tekla Capital Management. Since its founding, the company has raised a total of $59 million from leading institutional investors.
The proceeds from this funding will be used to advance the company’s lead developmental candidate, B-701, in the treatment of patients with metastatic bladder cancer or metastatic urothelial carcinoma (mUC), who have relapsed or are refractory to platinum therapy. “This funding allows us to expand our Phase 1b/2 trial of B-701 in combination with docetaxel and to initiate a Phase 1b/2 trial of B-701 in combination with atezolizumab,” said Stephen Lau, CEO of BioClin Therapeutics.
Cory Freedland, PhD, of Sofinnova Ventures and Joà’l Jean-Mairet, PhD, of Ysios Capital, joined the Board of Directors in conjunction with the financing. David Lacey, MD has been named Observer of the Board
“Over the last few years, there has been significant scientific advancement and understanding of FGFR3 biology and bladder cancer, both for FGFR3 itself as a potential driver of metastatic bladder cancer and its potential role in tumor inflammation. We are very excited about the B-701 program and its potential to enhance the treatment effects of control point inhibitors,” said Joel Jean-Mairet of Ysios Capital.
“We believe that targeted therapies, particularly FGFR3 in combination with immunotherapy, are an important area of development. In addition, we are excited to join the BioClin Syndicate and attract the David Lacey Caliber to the BioClin Team,” said Cory Freedland of Sofinnova. Dr. Dr. Lacey, formerly Senior Vice President of Discovery Research at Amgen, has over 20 years of scientific and senior experience in life sciences, focused on creating new medicines to make a difference in the lives of patients worldwide. During his time at Amgen, Dr. Lacey led an organization of more than 1,200 scientists across a portfolio of drug discovery and development programs in the therapeutic fields of hematology/oncology, inflammation, metabolic disorders and neuroscience. Dr. Dr. Lacey is currently a member of the Board of Nurix Inc. Atreca and Inbiomotion SL, acting as advisors to a number of academic institutions, biotechnological companies, are Venture Partners at Ysios Capital.
BioClin Therapeutics, Inc.
BioClin Therapeutic, Inc. Is a privately owned clinical stage drug development company developing biologics to address medical conditions in areas of high unmet need. The company’s leading candidate is B-701, a potential first-in-class human monoclonal antibody targeting FGFR3 (fibroblast growth factor receptor 3) B-701 is currently under assessment in the treatment of metastatic bladder cancer The first clinical study was a Phase 1b/2 study of B-701 in combination with docetaxel. The study includes cohorts in which patients with FGFR3 mutation or fusion will be enrolled; patients will be given B-701 plus docetaxel or B-701 alone as monotherapy. The second study evaluates the combination of B-701 and atezolizumab in mUC patients and will include those with overexpressed FGFR3 and those with FGFR3 mutation or fusion in their tumors. B-701 is also being tested in an ongoing research study sponsored to evaluate the combination of B-701 and pembrolizumab in mUC patients.
For more information, please visit BioClin’s website at www. Bioclin Therapy Come on,
Please note that this piece of work originally appeared in English at https://www.vcnewsdaily.com/BioClin%20Therapeutics/venture-funding.php. As Investocracy aims to bring global startup news and updates in both English and Japanese to you, it’s important that we attribute original source to you. If you have any questions/concerns please write to us at contact@investocracy.co
